COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

30,796 Articles (22,527 medRxiv, 8,269 bioRxiv)

Most recent first Previous |  Page 1685: Articles 16841-16850  | Next

Agreement between commercially available ELISA and in-house Luminex SARS-CoV-2 antibody immunoassays
Santano, R., Barrios, D., Crispi, F., Crovetto, F., Vidal, M., Chi, J., Izquierdo, L., Gratacos, E., Moncunill, G., Dobano, C.
10.1101/2021.03.09.21252401 — Posted: 2021-03-10
Immune response to SARS-CoV-2 variants of concern in vaccinated individuals
Becker, M., Dulovic, A., Junker, D., Ruetalo, N., Kaiser, P., Pinilla, Y., Heinzel, C., Haering, J., Traenkle, B., Wagner, T., Layer, M., Mehrlaender, M., Mirakaj, V., Held, J., Planatscher, H., Schenke-Layland, K., Krause, G., Strengert, M., Bakchoul, T., Althaus, K., Fendel, R., Kreidenweiss, A., Koeppen, M., Rothbauer, U., Schindler, M., Schneiderhan-Marra, N.
10.1101/2021.03.08.21252958 — Posted: 2021-03-10
Detection of autoimmune antibodies in severe but not in moderate or asymptomatic COVID-19 patients
Fakhro, A. D., Nasrallah, G. K., Khan, T., S. Cyprian, F., Al Ali, F., M.A. Ata, M., Taleb, S., A. Hssain, A., Eid, A. H., J. Abu-Raddad, L., Al-Khal, A., Al Thani, A. A., Marr, N., YASSINE, H. M.
10.1101/2021.03.02.21252438 — Posted: 2021-03-10
Incidence of SARS-CoV-2 infection according to baseline antibody status in staff and residents of 100 Long Term Care Facilities (VIVALDI study)
Krutikov, M., Palmer, T., Tut, G., Fuller, C., Shrotri, M., Williams, H., Davies, D., Irwin-Singer, A., Robson, J., Hayward, A., Moss, P., Copas, A., Shallcross, L. J.
10.1101/2021.03.08.21253110 — Posted: 2021-03-10
Site-specific steric control of SARS-CoV-2 spike glycosylation
Allen, J. D., Chawla, H., Samsudin, F., Zuzic, L., Shivgan, A. T., Watanabe, Y., He, W.-T., Callaghan, S., Song, G., Yong, P., Brouwer, P. J. M., Song, Y., Cai, Y., Duyvesteyn, H. M. E., Malinauskas, T., Kint, J., Pino, P., Wurm, M. J., Frank, M., Chen, B., Stuart, D. I., Sanders, R. W., Andrabi, R., Burton, D. R., Li, S., Bond, P. J., Crispin, M.
10.1101/2021.03.08.433764 — Posted: 2021-03-09
The FDA-approved drug cobicistat synergizes with remdesivir to inhibit SARS-CoV-2 replication
Shytaj, I. L., Fares, M., Lucic, B., Gallucci, L., Tolba, M. M., Zimmermann, L., Ayoub, A. T., Cortese, M., Neufeldt, C. J., Laketa, V., Chlanda, P., Fackler, O. T., Boulant, S., Bartenschlager, R., Stanifer, M., Savarino, A., Lusic, M.
10.1101/2021.03.09.434219 — Posted: 2021-03-09
COVIDrugNet: a network-based web tool to investigate the drugs currently in clinical trial to contrast COVID-19
Menestrina, L., Cabrelle, C., Recanatini, M.
10.1101/2021.03.05.433897 — Posted: 2021-03-09 Discussion: Onsite
A recombinant ACE2 Triple Decoy that traps and neutralizes SARS-CoV-2 shows enhanced affinity for highly transmissible SARS-CoV-2 variants
Tanaka, S., Nelson, G., Olson, A., Buzko, O., Higashide, W., Shin, A., Gonzales, M., Taft, J., Patel, R. S., Buta, S., Martin-Fernandez, M., Bogunovic, D. S., Spilman, P. R., Niazi, K., Rabizadeh, S., Soon-Shiong, P.
10.1101/2021.03.09.434641 — Posted: 2021-03-09
In vitro rapid inactivation of SARS-CoV-2 by visible light photocatalysis using boron-doped bismuth oxybromide
Ling, L., Carletti, T., Cheng, Z., Wang, R., Ren, Y., Westerhoff, P., Shang, C., Marcello, A., Chen, S.
10.1101/2021.03.09.434359 — Posted: 2021-03-09
Quantitative proteomics of hamster lung tissues infected with SARS-CoV-2 reveal host-factors having implication in the disease pathogenesis and severity
Suresh, V., Mohanty, V., Avula, K., Ghosh, A., Singh, B., Reddy, R. R. K., Suryawanshi, A. R., Raghav, S., Chattopadhyay, S., Prasad, P., Swain, R. K., Dash, R., Parida, A., Syed, G. H., Senapati, S.
10.1101/2021.03.09.434371 — Posted: 2021-03-09

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).